For pharmaceutical companies navigating the complex journey from clinical trial success to market entry, the final phase—commercialization—often represents the most…
Read More
The FDA plans its third rare disease policy change in just over a year
On October 14, 2026, the U.S. Food and Drug Administration (FDA) formally unveiled the "Rare Disease Framework Initiative," a comprehensive…
Read More
Pharma commercial vendor selection still runs on word of mouth and a Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the high-stakes transition from clinical development to commercial launch, the landscape of service providers remains remarkably…
Read More
Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the complex transition from clinical success to commercial launch, the process of selecting service providers—ranging from…
Read More
Pharma commercial vendor selection still runs on word of mouth: A Harvard MBA student aims to change that with Rx Almanac
For pharmaceutical companies navigating the complex journey from clinical trial success to market launch, the final hurdle is often the…
Read More
Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.
The pharmaceutical industry, a sector defined by rigorous clinical validation and data-driven R&D, paradoxically relies on archaic, informal methods when…
Read MorePharma commercial vendor selection still runs on word of mouth: A Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the complex transition from clinical research to commercial launch, the selection of service providers—ranging from distribution…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic diseases is undergoing a profound transformation, heralded by the recent approval of orforglipron, the first…
Read More
Colon Cancer Cells May Change Identity to Metastasize, Unveiling New Pathways for Therapeutic Intervention
A groundbreaking study has revealed that colorectal cancer cells possess a remarkable ability to alter their fundamental identity, a crucial…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic disorders is undergoing a profound transformation, heralded by the advent of oral small-molecule GLP-1 receptor…
Read More
